表紙
市場調査レポート

バイオシミラー/後発生物製剤の世界市場:機会および予測 (2014〜2020年)

World Biosimilars/Follow-on-Biologics Market - Opportunities and Forecasts, 2014 - 2020

発行 Allied Market Research 商品コード 341822
出版日 ページ情報 英文 120 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
バイオシミラー/後発生物製剤の世界市場:機会および予測 (2014〜2020年) World Biosimilars/Follow-on-Biologics Market - Opportunities and Forecasts, 2014 - 2020
出版日: 2015年09月01日 ページ情報: 英文 120 Pages
概要

世界のバイオシミラー/後発生物製剤市場は2014年に25億5,200万米ドルの収益を挙げました。同市場は2015年から2020年にかけ、CAGR49.1%で拡大し、265億5,513万米ドルになると予測されています。

当レポートでは、世界のバイオシミラー/後発生物製剤市場について調査し、市場の2014〜2020年の予測、市場の用途別、地域別、サービス別動向、および参入企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義
  • バイオシミラーに対する世界の規制当局の様々なアプローチ
  • バイオシミラー薬の安全問題
  • 主な調査結果
  • 法規制と償還シナリオ
  • 新興国がバイオシミラーの中心地
  • ポーターズファイブフォース分析
  • バリューチェーン分析
  • 治験
  • 市場シェア分析:2014年
  • 市場動向

第4章 技術別世界市場

  • モノクローナル抗体技術
  • 組換えDNA技術
  • クロマトグラフィ
  • NMR技術
  • 電気泳動
  • 質量分析
  • ウェスタンブロット法
  • バイオアッセイ

第5章 製品別世界のバイオシミラー市場

  • ヒト成長ホルモン
  • インスリン
  • インターフェロン
  • G-CSF
  • エリスロポエチン
  • モノクローナル抗体
  • ペプチド
  • その他

第6章 用途別世界市場

  • 血液疾患
  • 腫瘍疾患
  • 慢性・自己免疫疾患
  • 成長ホルモン欠乏
  • その他

第7章 サービル別世界市場

  • 研究開発、製造受託サービス
  • 治験

第8章 地域別市場

  • 北米
  • 欧州
  • アジア太平洋地域
  • 中南米

第9章 主要製品と近年の活動

第10章 企業プロファイル

  • Novartis
  • Synthon Pharmaceuticals, Inc
  • Teva Pharmaceutical Industries Ltd.
  • LG Life Sciences
  • Celltrion
  • Biocon
  • Hospira
  • Merck Serono
  • Biogen idec Inc.
  • Genentech

図表

目次

Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of biosimilars, ease in development and a quick approval process are some key driving factors that drive the growth of this market. Effective and timely formulated regulations facilitate the viability and balance between original and biosimilar products. Moreover, a favorable regulatory environment and the establishment of IPR protections are factors that boost the market growth. The upcoming patent expiration for blockbuster drugs has revolutionized the aspect of commercialization whilst triggering a large scale adoption of biosimilars. Biosimilars industry is facing problems relating to production efficiency and quantity. The lack of economies of scale for small scale manufacturers and absence of regulatory guidelines in lucrative regions such as China, US are hindering the growth of biosimilars market. However, strong government initiatives pertaining to production and approval is a key factor that would eventually reduce the impact of these restraints over the forecast period. Global biosimilars/follow-on-biologics market accounted for an overall revenue of $2,552.0 million in 2014 and it is estimated to generate an approximate revenue of $26,551.3 million by 2020, registering a CAGR of 49.1% from 2015 to 2020.

The product segment in the biosimilars market comprises of Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Colony Stimulating Factors and others. Biosimilars erythropoietin is the highest revenue generating biosimilars drug candidate owing to its high approval rate for commercialization. Interferon biosimilars are the fastest growing drugs in the biosimilars market. This growth is supplemented by the use of interferon biosimilars across a wide range of applications.

The biosimilars applications market is segmented into blood disorders, oncology diseases, chronic and autoimmune diseases and growth hormone deficiency. The application of biosimilars in blood disease treatment is the highest revenue generating segment owing to the high-priced reference biologics and frequent application. However, biosimilars applications in autoimmune and chronic diseases exhibit the highest potential due to the changing off patent scenario.

Based on geography, the biosimilars market is segmented across North America, Europe, Asia-Pacific and LAMEA. Asia Pacific and LAMEA exhibit a large scale demand for biosimilars due to the growing prevalence of chronic diseases in these regions. Collaboration with local players is a key opportunity for biosimilars in developing economies. Many companies such as, Amgen and Novartis are collaborating with Asian players to reach to the depth of the biopharmaceutical market. The absence of effective regulatory guidelines for product approval and commercialization limit the growth of the biosimilars market in North America. However, recent draft published by US FDA has approved first biosimilar in United States. This would eventually standardized the procedure of approval and commercialization of biosimilars in United States.

This report provides a comprehensive market share analysis of leading companies and highlights the competition in the market. Product launch is the key strategy adopted by the leading player of biosimilars industry. The key companies profiled in this report are Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc., and Genentech (Roche Group).

Key Benefits

This report provides a detailed analysis of drivers and factors that limit the market expansion

The report provides a financial market forecast for the next eight years by considering the 2014 as the base year for evaluation.

Comprehensive and quantitative data about changing market trends, competition and opportunities in biosimilars market are provided in the report

Use of Porters Five Forces model and SWOT analysis would help stakeholders in making strategic decisions

Deep dive analysis of leading market players and their key strategies, helps in better understanding the market dynamics

Identification of key investment pockets in the biosimilars market would help the stakeholders in making informed decisions

Key Deliverables

Global biosimilars/follow-on-biologics market is categorized into product types, applications and geography.

MARKET BY TYPES

  • Human growth hormone
  • Erythropoietin
  • Monoclonal antibodies
  • Insulin
  • Interferon
  • Granulocyte-Colony Stimulating Factor
  • Peptide
  • Others

MARKET BY APPLICATIONS

  • Blood disorders
  • Oncology diseases
  • Chronic and autoimmune diseases
  • Growth hormone deficiencies
  • Others

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Key Benefits
  • 1.2. Key Market Segment
  • 1.3. Research Methodology
    • 1.3.1. Primary Research
    • 1.3.2. Secondary Research
    • 1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond: what to expect by 2025
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market Definition
  • 3.2. Diverse approach of global regulators towards biosimilars
  • 3.3. Safety issues of biosimilar drugs
  • 3.4. Key Findings
    • 3.4.1. Top impacting factors
    • 3.4.2. Top winning strategies
    • 3.4.3. Top investment pockets
  • 3.5. Regulation and Reimbursement scenario
    • 3.5.1. Regulations in United States
    • 3.5.2. Regulations in Europe
    • 3.5.3. Regulation in Asia
    • 3.5.4. Comparison of Biosimilar medicine guidelines
  • 3.6. Emerging economies a hotspot for biosimilars market
    • 3.6.1. Brazil a treasure for the biosimilar manufacturers
    • 3.6.2. China the bulkmarket for biosimilars
    • 3.6.3. India an early adopter of biosimilars
  • 3.7. Porters five force analysis
    • 3.7.1. Higher bargaining of suppliers
    • 3.7.2. Moderate bargaining power of buyers
    • 3.7.3. Higher threats from substitutes due to lower switching cost
    • 3.7.4. Lower threats from new entrants due to technological and political barriers
    • 3.7.5. Higher competition among players
  • 3.8. Value chain analysis
    • 3.8.1. Primary activities
    • 3.8.2. Supportive activities
  • 3.9. Clinical trials
    • 3.9.1. MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
    • 3.9.2. Efficacy Study of Two Formulations of Erythropoietin
    • 3.9.3. Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anemia in Hematology and Oncology
    • 3.9.4. An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
  • 3.10. Market Share analysis, 2014
  • 3.11. Market Dynamics
    • 3.11.1. Drivers
      • 3.11.1.1. Growing pressure to reduce healthcare expenditure
      • 3.11.1.2. Various blockbusters going off patent
      • 3.11.1.3. High prevalence of chronic diseases among ageing population
      • 3.11.1.4. Favorable intervention from the developing economies
      • 3.11.1.5. Lower cost biosimilars drugs than original biologics
    • 3.11.2. Restraints
      • 3.11.2.1. High initial investment in research and development
      • 3.11.2.2. Stringent regulations in developed economies to restrict investment
      • 3.11.2.3. Medical Efficacy and Patient Safety
    • 3.11.3. Opportunities
      • 3.11.3.1. opportunities in Emerging economies
      • 3.11.3.2. Emergence of bio-betters drugs

CHAPTER 4: GLOBAL MARKET BY TECHNOLOGY

  • 4.1. Monoclonal Antibodies (MAb) Technology
    • 4.1.1. Drivers
  • 4.2. Recombinant DNA Technology (rDNA technology)
    • 4.2.1. Drivers
    • 4.2.2. Restraints & Opportunities
  • 4.3. Chromatography
    • 4.3.1. Protein sequencing
    • 4.3.2. Liquid chromatography (LC)
    • 4.3.3. Gas Chromatography (GC)
    • 4.3.4. Drivers
  • 4.4. Nuclear magnetic resonance (NMR) technology
    • 4.4.1. Drivers
  • 4.5. Electrophoresis
    • 4.5.1. Drivers
    • 4.5.2. Restraints & Opportunities
    • 4.5.3. Gel Electrophoresis
    • 4.5.4. Capillary Electrophoresis
  • 4.6. MASS SPECTROMETRY
    • 4.6.1. Drivers
    • 4.6.2. Restraints
  • 4.7. Western Blotting
    • 4.7.1. Drivers
  • 4.8. Bioassay
    • 4.8.1. Drivers
    • 4.8.2. Restraints
    • 4.8.3. Techniques in Bioassay

CHAPTER 5: GLOBAL BIOSIMILARS MARKET BY PRODUCT

  • 5.1. Human Growth Hormone
    • 5.1.1. Key market trends
    • 5.1.2. Key growth factors and opportunities
    • 5.1.3. Market size & forecast
  • 5.2. Insulin
    • 5.2.1. Key market trends
    • 5.2.2. Key growth factors and opportunities
    • 5.2.3. Market size & forecast
  • 5.3. Interferon
    • 5.3.1. Key market trends
    • 5.3.2. Key growth factors and opportunities
    • 5.3.3. Market size & forecast
  • 5.4. Granulocyte colony stimulating factor (G-CSF)
    • 5.4.1. Key market trends
    • 5.4.2. Key growth factors and opporunities
    • 5.4.3. Market size & forecast
  • 5.5. Erythropoietin
    • 5.5.1. Key market trends
    • 5.5.2. Key growth factors and opportunities
    • 5.5.3. Market size & forecast
  • 5.6. Monoclonal antibodies
    • 5.6.1. Key market trends
    • 5.6.2. Key growth factors and opportunities
    • 5.6.3. Market size & forecast
  • 5.7. Peptides
  • 5.8. Others
    • 5.8.1. Key market trends
    • 5.8.2. Key growth factors and opportunity

CHAPTER 6: GLOBAL MARKET BY APPLICATIONS

  • 6.1. Blood disorders
    • 6.1.1. Drivers
    • 6.1.2. Chemotherapy induce Anaemia
      • 6.1.2.1. Drivers
      • 6.1.2.2. RESTRAIN AND OPPORTINITIES
    • 6.1.3. Hemophilia
    • 6.1.4. Pulmonary embolism
      • 6.1.4.1. DRIVER
  • 6.2. Oncology diseases
    • 6.2.1. Driver
    • 6.2.2. Opportunities and restraints
    • 6.2.3. Lungs cancer
    • 6.2.4. Breast cancer
    • 6.2.5. Cervical cancer
    • 6.2.6. Colorectal cancer
    • 6.2.7. Prostate cancer
    • 6.2.8. Leukaemia
  • 6.3. Chronic and autoimmune diseases
    • 6.3.1. Diabetes
      • 6.3.1.1. Drivers
    • 6.3.2. Neutropenia
    • 6.3.3. Multiple sclerosis
      • 6.3.3.1. Drivers
      • 6.3.3.2. Restraints and opportunities
    • 6.3.4. Cystic Fibrosis
    • 6.3.5. Rheumatoid arthritis (RA)
      • 6.3.5.1. Drivers
      • 6.3.5.2. Restraints
    • 6.3.6. Acromegaly
      • 6.3.6.1. drivers
    • 6.3.7. Leprosy
  • 6.4. Growth hormone deficiency
    • 6.4.1. Drivers
  • 6.5. Others
    • 6.5.1. Gaucher disease
    • 6.5.2. Osteoporosis

CHAPTER 7: GLOBAL MARKET BY SERVICES

  • 7.1. Contract Research and Manufacturing Services
    • 7.1.1. Drivers
    • 7.1.2. Restraints & Opportunities
  • 7.2. Clinical trials
    • 7.2.1. Drivers & Restraints
    • 7.2.2. Phase I
    • 7.2.3. Phase II
    • 7.2.4. Phase III

CHAPTER 8: GLOBAL BIOSIMILARS MARKET BY GEOGRAPHY

  • 8.1. North America
    • 8.1.1. Key market trends
    • 8.1.2. Key growth factors and opportunities
    • 8.1.3. Market size & forecast
  • 8.2. Europe
    • 8.2.1. Key market trends
    • 8.2.2. Key growth factors and opportunities
    • 8.2.3. Market size & forecast
  • 8.3. Asia-Pacific
    • 8.3.1. Key market trends
      • 8.3.1.1. India
        • 8.3.1.1.1. COMPETITIVE SCENARIO
      • 8.3.1.2. China
        • 8.3.1.2.1. COMPETITIVE SCENARIO
      • 8.3.1.3. Australia
        • 8.3.1.3.1. COMPETITIVE SCENARIO
    • 8.3.2. Key growth factors and opporunities
    • 8.3.3. Market size & forecast
  • 8.4. LAMEA
    • 8.4.1. Key market trends
    • 8.4.2. Key growth factors and opportunities
    • 8.4.3. Market size & forecast

CHAPTER 9: KEY PRODUCTS AND RECENT ACTIVITIES

  • 9.1. US
    • 9.1.1. Hospira
      • 9.1.1.1. Recent Activities
  • 9.2. Europe
    • 9.2.1. Stada Arzneimittel AG
      • 9.2.1.1. Recent Activities
    • 9.2.2. Hexal AG
    • 9.2.3. Ratiopharm GmbH
    • 9.2.4. Bioton
      • 9.2.4.1. Recent Activities
    • 9.2.5. Sandoz GmbH
      • 9.2.5.1. Recent Activities
  • 9.3. India
    • 9.3.1. Dr.Reddy's Labs (DRL)
      • 9.3.1.1. Recent Activities
    • 9.3.2. Intas Pharmaceuticals Ltd.
      • 9.3.2.1. Recent Activities
    • 9.3.3. Wockhardt Limited
      • 9.3.3.1. Recent Activities
    • 9.3.4. Biocon Limited
      • 9.3.4.1. Recent Activities
    • 9.3.5. Shantha Biotechnics Limited
      • 9.3.5.1. Recent Activities
    • 9.3.6. Reliance Life Sciences
  • 9.4. Korea
    • 9.4.1. Dong-A Pharmaceutical Co., Ltd
      • 9.4.1.1. Recent Activities
    • 9.4.2. LG Life Sciences
      • 9.4.2.1. Recent Activities
    • 9.4.3. Celltrion Pharm, Inc.
      • 9.4.3.1. Recent Activities
  • 9.5. Others
    • 9.5.1. Teva Pharmaceutical Industries Ltd.
      • 9.5.1.1. Recent Activities

CHAPTER 10: COMPANY PROFILES

  • 10.1. Novartis (Sandoz)
    • 10.1.1. Company overview
    • 10.1.2. Company snapshot
    • 10.1.3. Operating business segment overview
    • 10.1.4. Business performance
    • 10.1.5. Key strategies
      • 10.1.5.1. Primary Strategies: Clinical Trials
      • 10.1.5.2. secondary Strategies: approval
    • 10.1.6. SWOT analysis
  • 10.2. Synthon Pharmaceuticals, Inc.
    • 10.2.1. Company overview
    • 10.2.2. Company snapshot
    • 10.2.3. Operating business segment overview
    • 10.2.4. Key strategies
      • 10.2.4.1. Primary Strategies: agreement
      • 10.2.4.2. secondary Strategies: clinical trials
    • 10.2.5. SWOT analysis
  • 10.3. Teva Pharmaceutical Industries Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Operating business segment overview
    • 10.3.4. Business performance
    • 10.3.5. Key strategies
      • 10.3.5.1. Primary Strategies: approval
      • 10.3.5.2. secondary Strategies: clinical trials
    • 10.3.6. SWOT analysis
  • 10.4. LG Life Sciences
    • 10.4.1. Company overview
    • 10.4.2. Company snapshot
    • 10.4.3. Operating business segment overview
    • 10.4.4. Business performance
    • 10.4.5. Key strategies
      • 10.4.5.1. Primary Strategies: Collaboration
    • 10.4.6. SWOT analysis
  • 10.5. Celltrion
    • 10.5.1. Company overview
    • 10.5.2. Company snapshot
    • 10.5.3. Operating business segment overview
    • 10.5.4. Business Performance
    • 10.5.5. Key strategies
      • 10.5.5.1. Primary Strategies: approval
    • 10.5.6. SWOT analysis
  • 10.6. Biocon
    • 10.6.1. Company overview
    • 10.6.2. Company snapshot
    • 10.6.3. Operating business segment overview
    • 10.6.4. Business Performance
    • 10.6.5. Key strategies
      • 10.6.5.1. Primary Strategy: product launch
      • 10.6.5.2. secondary Strategy: clinical trial
    • 10.6.6. SWOT analysis
  • 10.7. Hospira
    • 10.7.1. Company overview
    • 10.7.2. Company snapshot
    • 10.7.3. Operating business segment overview
    • 10.7.4. Business performance
    • 10.7.5. Key strategies
      • 10.7.5.1. Primary Strategies: approval
      • 10.7.5.2. secondary Strategies: clinical trials
    • 10.7.6. SWOT analysis
  • 10.8. Merck Serono (Merck Group)
    • 10.8.1. Company overview
    • 10.8.2. Company snapshot
    • 10.8.3. Operating business segment overview
    • 10.8.4. Business performance
    • 10.8.5. Key strategies
      • 10.8.5.1. Primary Strategies: partnership and product launch
    • 10.8.6. SWOT analysis
  • 10.9. Biogen idec Inc.
    • 10.9.1. Company overview
    • 10.9.2. Company snapshot
    • 10.9.3. Operating business segment overview
    • 10.9.4. Business performance
    • 10.9.5. Key strategies
      • 10.9.5.1. Primary Strategies: agreement and joint venture
    • 10.9.6. SWOT analysis
  • 10.10. Genentech (Roche Group)
    • 10.10.1. Company overview
    • 10.10.2. Company snapshot
    • 10.10.3. Operating business segment overview
    • 10.10.4. Key strategies
      • 10.10.4.1. Primary Strategies: Investment and license
    • 10.10.5. SWOT analysis

List of Tables

  • TABLE 1: BIOSIMILARS MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 2: BIOSIMILARS RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 3: BIOSIMILARS DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
  • TABLE 4: BIOSIMILARS GUIDELINES ADOPTED BY REGIONS
  • TABLE 5: COMPARISON OF BIOSIMILAR MEDICINE GUIDELINES BY GEOGRAPHY (2013)
  • TABLE 6: BIOSIMILARS DEVELOPMENT 2013 (LATIN AMERICA)
  • TABLE 7: OFF GOING PATENTS 2013-2016
  • TABLE 8: PREVALENCE OF TOP TWO CHRONIC DISEASES (2013)
  • TABLE 9: BIOSIMILAR DEVELOPMENT STATUS (2013)
  • TABLE 10: GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2014-2020 ($MILLION)
  • TABLE 11: PATENTS STATUS FOR THE HUMAN GROWTH HORMONE (BIOLOGICS)
  • TABLE 12: PATENT EXPIRATION STATUS FOR HUMAN GROWTH HORMONE DURING 2014-2020 (BIOLOGICS)
  • TABLE 13: GLOBAL HGH BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)
  • TABLE 14: PATENTS APPROVED FOR INSULIN (BIOLOGICS)
  • TABLE 15: GLOBAL INSULIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)
  • TABLE 16: PATENTS APPROVED FOR INTERFERON (BIOLOGICS)
  • TABLE 17: PATENT EXPIRATION STATUS FOR INTERFERON DURING, 2014-2020 (BIOLOGICS)
  • TABLE 18: GLOBAL INTERFERON BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 19: PATENT EXPIRATION STATUS FOR G-CSF BIOSIMILARS DURING, 2014-2020 (BIOLOGICS)
  • TABLE 20: GLOBAL G-CSF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 21: PATENTS STATUS FOR ERYTHROPOIETIN (BIOLOGICS)
  • TABLE 22: PATENT EXPIRATION STATUS FOR ERYTHROPOIETIN DURING 2014-2020 (BIOLOGICS)
  • TABLE 23: GLOBAL ERYTHROPOIETIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 24: DRUG PATENT EXPIRATION FOR MONOCLONAL ANTIBODIES (BIOLOGICS)
  • TABLE 25: PATENT EXPIRATION STATUS FOR MONOCLONAL ANTIBODIES DURING, 2014-2020 (BIOLOGICS)
  • TABLE 26: GLOBAL MAB BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 27: GLOBAL PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014 -2020 ($MILLION)
  • TABLE 28: HIRUDIN BIOSIMILAR CANDIDATE STATUS
  • TABLE 29: GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
  • TABLE 30: GLOBAL BLOOD DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 31: GLOBAL ONCOLOGY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 32: GLOBAL CHRONIC AND AUTOIMMUNE DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 33: GLOBAL GROWTH HORMONE DEFICIENCY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 34: GLOBAL OTHER DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 35: GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 36: NORTH AMERICA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATION, 2014-2020 ($MILLION)
  • TABLE 37: BIOSIMILARS COMMERCIALLY AVAILABLE IN EUROPEAN UNION
  • TABLE 38: EUROPE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
  • TABLE 39: ASIA-PACIFIC BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
  • TABLE 40: LAMEA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)

List of Figures

  • FIG. 1: TOP FACTORS IMPACTING BIOSIMILARS MARKET (2014-2020)
  • FIG. 2: TOP WINING STRATEGIES FOR BIOSIMILARS MARKET DURING (2010-2015)
  • FIG. 3: TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENTS (2010-2015)
  • FIG. 4: TOP INVESTMENT POCKETS OF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET PRODUCTS, 2014-2020
  • FIG. 5: KEY ACHIEVEMENTS FOR BIOSIMILAR REGULATORS (2010)
  • FIG. 6: REGULATORY FRAMEWORK FOR BIOSIMILAR PRODUCTS IN CHINA
  • FIG. 7: PORTERS FIVE FORCE ANALYSIS OF BIOSIMILARS MARKET
  • FIG. 8: VALUE CHAIN ANALYSIS OF BIOSIMILARS MARKET
  • FIG. 9: IMPACT ANALYSIS OF STAKEHOLDERS INVOLVED IN PRIMARY ACTIVITIES (2014-2020)
  • FIG. 10: MARKET SHARE ANALYSIS OF BIOSIMILARS MARKET (2014)
  • FIG. 11: IMPACT ANALYSIS OF PRODUCT MARKET SEGMENTS (2014, 2020-2025)
  • FIG. 12: NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
  • FIG. 13: IMPACT ANALYSIS OF APPLICATION MARKET SEGMENTS (2014-2020-2025)
  • FIG. 14: IMPACT OF REGULATION ON VARIOUS GEOGRAPHIES, 2012
  • FIG. 15: NET REVENUE GENERATION BY GEOGRAPHY (2013)
  • FIG. 16: NET REVENUE GENERATION BY BUSINESSES (2013)
  • FIG. 17: SWOT ANALYSIS OF NOVARTIS (SANDOZ)
  • FIG. 18: SWOT ANALYSIS OF SYNTHON PHARMACEUTICALS
  • FIG. 19: NET REVENUE GENERATION BY GEOGRAPHY (2013)
  • FIG. 20: NET REVENUE GENERATION BY BUSINESSES (2013)
  • FIG. 21: SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • FIG. 22: NET REVENUE GENERATION (2011-2013)
  • FIG. 23: SWOT ANALYSIS OF LG LIFE SCIENCES
  • FIG. 24: NET PROFIT DURING 2011-2013
  • FIG. 25: SWOT ANALYSIS OF CELLTRION
  • FIG. 26: REVENUE GENERATED BY BUSINESS UNITS (2013)
  • FIG. 27: SWOT ANALYSIS OF BIOCON
  • FIG. 28: NET SALES BY GEOGRAPHY (2013)
  • FIG. 29: NET SALES BY BUSINESS UNITS (2013)
  • FIG. 30: SWOT ANALYSIS OF HOSPIRA
  • FIG. 31: NET SALES BY GEOGRAPHY (2013)
  • FIG. 32: NET SALES BY BUSINESS UNITS (2013)
  • FIG. 33: SWOT ANALYSIS OF MERCK SERONO
  • FIG. 34: NET SALES BY GEOGRAPHY (2013)
  • FIG. 35: NET SALES BY BUSINESS UNITS (2013)
  • FIG. 36: SWOT ANALYSIS OF BIOGEN IDEC INC.
  • FIG. 37: SWOT ANALYSIS OF GENENTECH
Back to Top